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Abstract. Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local
diseases such as ulcerative colitis, Crohn’s disease, irritable bowel syndrome, chronic pancreatitis, and
colonic cancer. In addition, the colon can be a potential site for the systemic absorption of several drugs to
treat non-colonic conditions. Drugs such as proteins and peptides that are known to degrade in the
extreme gastric pH, if delivered to the colon intact, can be systemically absorbed by colonic mucosa. In
order to achieve effective therapeutic outcomes, it is imperative that the designed delivery system
specifically targets the drugs into the colon. Several formulation approaches have been explored in the
development colon-targeted drug delivery systems. These approaches involve the use of formulation
components that interact with one or more aspects of gastrointestinal (GI) physiology, such as the
difference in the pH along the GI tract, the presence of colonic microflora, and enzymes, to achieve colon
targeting. This article highlights the factors influencing colon-specific drug delivery and colonic bioavail-
ability, and the limitations associated with CDDS. Further, the review provides a systematic discussion of
various conventional, as well as relatively newer formulation approaches/technologies currently being
utilized for the development of CDDS.
KEY WORDS: colon targeting; factors affecting colon delivery; future trends; novel approaches;
traditional approaches.
INTRODUCTION
Colon-targeted drug delivery has been the focus of nu-
merous studies in recent years due to its potential to improve
treatment of local diseases affecting the colon, while minimiz-
ing systemic side effects. Some examples of disease states
which impact the colon include Crohn’s disease (CD), ulcera-
tive colitis (UC), and irritable bowel syndrome (IBS) (1).
Some of the frequently used drugs for the treatment of these
ailments include sulfasalazine, dexamethasone, hydrocorti-
sone, metronidazole, prednisolone, and others (2).
The delivery of these drugs specifically to the colon with-
out being absorbed first in the upper gastrointestinal (GI)
tract allows for a higher concentration of the drug to reach
the colon with minimal systemic absorption (3). The colonic
contents have a longer retention time (up to 5 days), and the
colonic mucosa is known to facilitate the absorption of several
drugs, making this organ an ideal site for drug delivery (3,4).
A drug can be delivered to the colon via the oral, or the rectal
route. Oral dosage forms are the most preferred delivery
route for colon-specific delivery due to their convenience
(4). Oral dosage forms also allow for a greater degree of
flexibility in their manufacturing, design, improved patient
adherence, relatively safe administration, and they do not
require sterile preparation (2). Direct rectal delivery of drugs
is challenging with respect to targeting a drug to specific sites
within the colon (2,4). Additionally, the extent of drug distri-
bution varies for different rectal dosage forms depending on
their spreading capacity and retention time.
The success of a colon-specific drug delivery system
(CDDS) depends on the drug’s physico-chemical properties,
the type of delivery system, all other factors which may influ-
ence the GI transit time, as well as the degree of interaction
between the drug and the GI tract (1). It is essential for oral
CDDS to protect the drug from being released in the stomach
and small intestine (4). Thus, the approaches used in develop-
ing a CDDS are aimed at delaying the drug release until the
system reaches the colon, with some strategies demonstrating
better success than others. Several marketed formulations
report the use of a combination of conventional and newer
approaches discussed above (Table I).
DRUG CRITERIA FOR A COLON-SPECIFIC DELI
VERY
Drugs which are meant to be incorporated into a colon-
specific delivery system should fulfill one or more of the
following physico-chemical/therapeutic criteria (1,4). First,
these drugs should exhibit local effects in the colon to treat
intestinal diseases. Peptide drugs like amylin and non-peptide
drugs such as oxyprenolol are some examples of agents with
these effects. Secondly, these drugs may demonstrate a sub-
optimal absorption in the upper gastrointestinal tract. This
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includes antianginal drugs such as isosorbide dinitrate.
Agents used in the treatment of colon or rectal cancers
(e.g., 5-flurouracil and capecitabine) are also ideal candi-
dates for CDDS. The remaining criteria include a high
likelihood of the drug’s degradation in the stomach by the acidic
environment or enzymes (e.g., peptide drugs like insulin and
gonadorelin), or a high risk for first-pass metabolism (e.g.,
corticosteroids).
LIMITATIONS OF COLONIC DRUG DELIVERY
The development of a colon-specific drug delivery system is
associated with specific limitations and challenges. A predominant
and an obvious challenge is the fact that the colon is located in the
distal part of the gastrointestinal tract (GIT). An orally adminis-
tered dosage form has to traverse the entire alimentary canal in
order to reach the target site. The GIT physiology is complex and
has a wide range of pH values, fluid volumes, and transit times.
Moreover, the presence of food and metabolic enzymes also
increases the physiological complexity. These factors are an obsta-
cle to the reliable and efficient delivery of drugs to the colon.
Another factor is the drug solubility. Due to a low colonic luminal
fluid volume, higher viscosity, and a neutral pH, the solubilization
of the drug could be a rate-limiting factor for colonic absorption.
Finally, maintaining the stability of the drug in the colon can be a
matter of concern. The non-specific interactions of the drug with
the colonic content e.g., dietary residues, intestinal secretions,
mucus, or fecal matter can have a negative influence on the
stability of the drug (5). In addition, the colonic bacterial enzymes
may also degrade the drug, rendering it ineffective.
FACTORS INFLUENCING COLON-SPECIFIC DRUG
DELIVERYAND COLONIC BIOAVAILABILITY
Several factors may influence the formulation/
development of a colon-specific drug delivery system
(CDDS) and the colonic bioavailability of the drugs (2,6).
Some of these factors are briefly discussed below.
Anatomical/Physiological Factors
The human large intestine is approximately 1.5-m long and
forms the colon (ascending, transverse, and descending), with a
small distal part forming the rectum. The colon is 2–3 in. in
diameter, and its lumen is lined with mucus. The physiology of
the colon differs significantly from other segments of the gastro-
intestinal tract (GIT) (Table II). Moreover, the physiology and
the physical properties of the colonic contents also differ be-
tween the ascending, transverse, descending, and sigmoidal co-
lon. In addition, there exists variability inmovement of food and
dosage forms across the colon, which may present a challenge in
the development of colonic drug delivery systems (7). Another
Table I. Currently Marketed Formulations





- Asacol® DR tablets
- Pentasa® TR capsules
Sulfasalazine
- Azulfidine EN-tabs® DR tablets
Prednisone
- Rayos® DR tablets
Budesonide
-MMX® Multi-matrix tablets
- Uceris® ER tablets
- Clipper® Gastro-resistant prolonged-release tablets
Prednisolone (Colal-Pred®) Oral colon-targeted pellets
Metronidazole (Flagyl® ER) ER tablets
Azathioprine (Azasan®) IR tablets
Mercaptopurine (Purinethol®) IR tablets
Cyclosporine (Gengraf®) IR capsules, oral solution
Diverticulosis and diverticulitis Methylcellulose (Citrucel®) Oral powder, IR tablet
Psyllium (Metamucil®) Oral powder, IR capsule
Mesalazine (Asacol®) DR tablets
Rifaximin (Xifaxan®) IR tablets
Colonic amoebiasis Doxycycline (Doryx®) DR tablets
Metronidazole (Flagyl® ER) ER tablets
Irritable bowel syndrome Methylcellulose (Citrucel®) Oral powder, IR tablets
Psyllium (Metamucil®) Oral powder, IR capsules
Loperamide (Imodium®) IR capsules
Dicyclomine (Bentyl®) IR capsules, IR tablets
Hyoscyamine (Levbid®) ER tablets
Lubiprostone (Amitiza®) Soft gelatin IR capsule
Linaclotide (Linzess®) IR capsules
Rifaximin (Xifaxan®) IR tablets
Amitriptyline (Elavil®) IR tablets
IR immediate release, ER extended release, DR delayed release, TR timed release
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physiological factor that affects colonic drug delivery and bio-
availability is the variation in pH of the GIT. Significant intra-
and inter-subject variability in the pH of the GIT have been
observed between disease states, fasted/fed states, sexes, and
ages in humans (8–10). Factors such as the viscosity and volume
of colonic fluids, the presence of microbial enzymes, and the
resulting colonic metabolism are other important factors influ-
encing CDDS performance which is discussed further.
Intestinal-Colonic Transit Time
The intestinal-colonic transit time plays an important role
in the performance of CDDS and the colonic bioavailability of
drugs. The transit times are also influenced by colonic disease
states such as UC and CD. Patients with UC are known to
have shorter colonic times (~24 h) compared to healthy sub-
jects (~52 h) (11). Similarly, Rana et al. showed that in patients
with IBD, the orocecal transit time was delayed (12). The
transit of dosage forms generally depends on the time of
administration, presence/absence of food, and the type of
dosage form. Stubbs et al. studied the effect of dawn and dusk
on the motility of dosage forms in the colon. The results
showed that colonic transit was delayed during sleep, and
larger dosage forms, e.g., capsules transited faster compared
to smaller dosage forms, e.g., dispersed particles (13).
Colonic Fluid Volume
The average human food intake is approximately 1.5 kg/
day and mainly consists of undigested proteins, carbohydrates,
and fats. These food components may serve as substrates for
the microbial enzymes in the colon (14). The colon has a high
water-absorbing capacity and can absorb ~90% of the water
entering the colon (15). The colonic fluid volume is calculated
to be in the range of 1–44 ml with an average volume of
approximately 13 ml (16). Due to this low volume of colonic
fluids, the dissolution of drugs from the dosage forms becomes
challenging and may affect the local drug bioavailability.
Viscosity of Colonic Luminal Contents
Due to a higher water-absorbing capacity, the viscosity of
the colonic luminal contents is higher than upper GIT contents
and presents a challenge for the dissolution of CDDS.
Moreover, the viscosity of the contents progressively increases
as it transits from the ascending colon towards the descending
colon, resulting in a reduced drug dissolution and mucosal
absorption (17). Viscosity also influences the penetration of
the drug into the disease-causing bacteria in the colon. The
mobility of bacteria in the colon has been shown to be depen-
dent on the viscosity of colonic contents (18).
Colonic pH
The pH varies significantly between different regions of
the GIT. For example, the pH of gastrointestinal contents can
be as low as 1 to 2 in the stomach and rise to 7.5 in the distal
small intestine (19,20). The pH then declines from the end of
the small intestine to the colon and gradually increases once
again in the colon (19,20). The pH of the colon may be
influenced by a carbohydrate rich diet. This is due to the
fermentation of polysaccharides by colonic bacteria and sub-
sequent formation of short chain fatty acids (21). Similarly,
polysaccharide-based drugs may also alter colonic pH.
Laxative drugs like lactulose are known to be fermented by
colonic bacteria to produce lactic acid and reduce colonic pH
(22). Gastrointestinal disease states such as UC have also been
found to influence the colonic pH (23). The pH of the colon
affects the pharmacokinetic and pharmacodynamic behavior
of a CDDS by influencing the solubility of drugs in the colonic
fluid. Moreover, if one or more components of the dosage
form are pH-sensitive, for example, a pH-sensitive coating
membrane, the effect of colonic pH is even more pronounced
on the drug release.
Colonic Enzymes and Metabolism
The colon is known to consist of over 400 different spe-
cies of aerobic and anaerobic microorganisms like Escherichia
coli and Clostridium species, respectively (24). These bacteria
contain several hydrolytic and reductive metabolizing
enzymes (25). The colonic enzymes catalyze a range of reac-
tions, including the metabolism of xenobiotics (e.g., drugs) and
other biomolecules (e.g., bile acid), deactivation of harmful
metabolites as well as carbohydrate and protein fermentation
(26). Polysaccharides such as chitosan, guar gum, pectin, etc.,
are commonly employed as release rate-controlling compo-
nents in colon-targeted dosage forms. These polysaccharides
are known to be resistant to gastric and intestinal enzymes, but
are metabolized by anaerobic bacteria in the colon (27–29).
Table II. Variations in the Physiology of Human Gastro-intestinal Tract (2,77,84)
Organ Contents pH
Stomach Thin soluble mucus, HCl, intrinsic factor, pepsin, lipases, gastrin, histamine, serotonin, somatostatin 1–1.5
Small intestine Chyme (from stomach), alkaline mucus, intestinal juice which is mostly water, motilin,
cholecystokinin, brush border enzymes (maltase, sucrose, lactase, enterokinase and
carboxypeptidase) Bile (which contains electrolytes, fatty substances, bile salts and pigments),
pancreatic juice (a bicarbonate-rich fluid containing enzymes)
5–7.5
Cecum Mucus, enteric bacteria, vitamins, food residue, gases such as carbon dioxide and methane 5.5–7
Ascending colon Mucus, enteric bacteria, vitamins, food residue, gases such as carbon dioxide and methane 5.7–6.9
Transverse colon Mucus, enteric bacteria, vitamins, food residue, gases such as carbon dioxide and methane 5.8–7.4
Descending colon Mucus, enteric bacteria, vitamins, food residue, gases such as carbon dioxide and methane 6.3–7.7
Rectum Undigested food residues, mucus, epithelial cells from the intestinal lining, numerous bacteria
(millions), some remaining water
~7
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Drugs are also known to be susceptible to biotransformation
by colonic enzymes. The metabolism of drugs by the colonic
enzymes may result in the formation of metabolites that are
pharmacologically active, inactive, or sometimes even harmful
(30,31). Formation of a pharmacologically active metabolite
by the colonic metabolism of drugs is a commonly used “pro-
drug” approach for the colon-specific drug delivery systems
(32).
Formulation Factors
The formulation factors that influence colonic drug deliv-
ery and bioavailability includes physicochemical properties of
the drugs, the dose, and the dosage form factors. Due to the
lower amount (1–44 ml) of colonic fluid available for dissolu-
tion, the solubility and the dose of a drug become important
factors for its colonic bioavailability. Although the highly
potent drug budesonide (dose, 9 mg) has a lower aqueous
solubility, it is absorbed well in the colon and is used
successfully in the treatment of UC (33). Mesalamine has
a significantly higher solubility (3.64 mg/ml) compared to
budesonide (0.24 mg/ml); however, it also has a significantly
higher dose (4.8 g daily) which becomes a rate-limiting factor
for its colonic absorption (34). Finally, the technology used in
the dosage form development can also influence the colonic
bioavailability of drugs. Useris® andEntocort EC® are current-
ly approved budesonide products for the treatment of UC and
CD, respectively (35). Useris® is a multi-matrix (MMX)-based
delayed-release tablets, which ensures the drug release in the
colon, while Entocort EC® is a capsule which releases the drug
in the ileum to treat CD.
CONVENTIONAL APPROACHES FOR ACHIEVING
COLONIC DELIVERY
Prodrugs
Prodrugs are inactive derivatives of a drug molecule
which release the active ingredient once they are hydrolyzed
by enzymes such as those in the colon (2,36). In order to
optimize drug delivery specific to the colon, the extent of this
hydrolysis should be minimal in the upper portions of the
gastrointestinal tract and much more extensive in the colon.
Azo conjugates are one of the most researched groups of
compounds that fall into this category (37,38). However, this
is not a very flexible method because it relies on the functional
groups of the drug molecule (4). Kim et al. synthesized a
prodrug of metronidazole, which was metabolized to the ac-
tive drug, metronidazole when placed in rats’ cecal contents
(39). Unlike metronidazole, this prodrug did not metabolize in
the small intestine, and the systemic absorption of this prodrug
was also found to be much lower compared to that of oral
metronidazole (39). In another study, Kim et al. prepared a
prodrug of metronidazole, using a sulfate group, and showed
that that this formulation remained intact in the upper intes-
tine, but was cleaved in the presence of rat cecal contents and
active metronidazole was released. Similar to the first pro-
drug, much less of the conjugated prodrug was degraded and
absorbed in the small intestine compared to the active drug
after oral administration. Therefore, a minimal amount was
absorbed into systemic circulation (40). Vaidya et al. utilized
the prodrug approach by conjugating metronidazole with pec-
tin and compared the drug release from this formulation to
that from pectin microspheres which physically entrapped the
drug (41). The pectin-metronidazole (PT-ME) prodrug
showed significantly reduced drug release in the upper GIT
compared to pectin microspheres containing metronidazole.
In vitro and in vivo studies revealed that conjugating the drug
to pectin can successfully target its delivery to the colon since
no drug release occurred at an acidic pH from the PT-ME
prodrug while nearly 100% of the metronidazole physically
entrapped in pectin microspheres was released in this same
environment. A significantly higher fraction of the drug was
released from the PT-ME prodrug in the colon (41).
Another way to assist a drug formulation to remain intact
as it passes through the stomach and small intestine is for it to
be covalently linked to a carrier. A drug can bind to carrier
molecules such as cyclodextrin, glucuronide, dextran, and
amino acids. It can also be linked to a carrier through an azo
bond. All of these bonds are broken down by colonic bacteria
or enzymes (3). Modasiya et al. studied the use of sodium
alginate (Na-Alg) and hydroxypropyl methylcellulose
(HPMC) as carriers for the successful delivery of matrix,
enteric-coated, and compression-coated tablets of curcumin
to the colon (42). The in vitro results showed that the drug
release was rapid from the matrix, and from the enteric-coated
tablets in conditions representing the stomach and small in-
testine. It was also observed that increasing HPMC levels
significantly restricted the release of curcumin in the upper
GIT and assisted in the delivery of curcumin specifically to the
colon.
Colon-Specific Biodegradable Delivery Systems
The colon contains many species of anaerobic bacteria
which obtain their energy by fermenting substrates such as
polymers which have not yet been digested. Bacteroides,
eubacteria, clostridia, enterococci, and enterobacteria are
some examples of these colon-specific species, and they pro-
duce numerous enzymes such as glucuronidase, xylosidase,
nitroreductase, and azoreductase to ferment these polymers
(10,43,44). Since these enzymes are localized to the colon, this
appears to be a more promising approach for colon-specific
delivery (4,45). Polymers used in the development of CDDS
can be chemically modified, and these modifications can in-
fluence the extent of enzymatic degradation. For example,
Roos et al. synthesized the acetyl derivative of guar gum
(AcGGM) and used this polymer to make a hydrogel of
bovine serum albumin (BSA) (46). They observed that the
rate of hydrolysis for modified AcGGM by β-mannase was
affected by its degree of substitution (DS). As DS increased,
the hydrolysis rate actually decreased, indicating that the side
chain hindered the enzyme. On the other hand, the addition of
β-mannase significantly enhanced BSA release, with 95% of
the BSA released after 8 h in the presence of this enzyme, and
only 60% was released in its absence. Azo-aromatic polymers,
which are among the most researched groups of compounds
used as prodrugs, are susceptible to degradation by azoreduc-
tases (18,19). Therefore, they can be used to coat the drug
molecules such as peptides to protect them from degradation
by peptidases in the stomach and small intestine while still
permitting drug release in the colon. Hita et al. carried out a
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study in which metronidazole capsules were coated with a film
of azo-aromatic polymers, and polymers sensitive to pH. The
in vitro and in vivo results revealed that the microbiota specific
to the colon degraded these polymers and released the met-
ronidazole locally in the colon (47).
Matrix-Based Systems
Another approach towards colon-targeted drug delivery
includes embedding the drug in polymer matrices to trap it
and release it in the colon. These matrices can be pH-sensitive
or biodegradable. Ahmad et al. developed matrix tablets con-
taining metronidazole using a natural polymer called Assam
Bora rice starch (48). The prepared tablets were evaluated by
in vitro drug release studies using 0.1 N HCl, phosphate buffer
with a pH of 7.4, and goat cecal content. The results showed
that the tablets exhibited a sustained release of the drug in the
alkaline environment, which was believed to be due to erosion
and dissolution of the polymer during its prolonged exposure
to this environment (48). The release of the drug, however,
was observed throughout the GIT. This indicated that these
matrix tablets were not colon-specific delivery systems, but
rather controlled-release systems.
Timed-Release Systems
Timed-released formulations are based on the drug being
released in the colon after a specified amount of time (3). This
approach is dependent on the transit time through the small
intestine, which is and known to vary between 3 and 4 h (2,49).
Gastric emptying time is inconsistent between individuals and
also fluctuates depending on food intake (50). Additionally,
diseases associated with the colon, such as irritable bowel
syndrome and ulcerative colitis can influence transit time
through the colon (4). Gazzaniga et al. used a combination
of pH-sensitive polymers and a timed-release approach to
achieve colon-specific delivery (51). A formulation consisting
of a drug-containing core enclosed within three polymeric
layers (a hydrophilic layer sandwiched between two pH-
sensitive layers) was developed. The in vitro evaluation results
revealed a sustained drug release due to pH protection and
hydrogel formation.
Bioadhesive Systems
Bioadhesive systems allow a formulation to remain in
contact within an organ, in this case the colon, for a long
period of time to assist poorly absorbable drugs to be
absorbed (48,52). Some of the polymers which have been
explored as bioadhesive components for these systems include
polycarbophils, polyurethanes, and polyethylene oxide (3).
Ahmad et al. used Assam Bora rice starch to develop a bio-
adhesive microsphere (BAM) for targeting the delivery of
metronidazole to the colon (48). These BAMs were found to
have higher retention time in the colon, and helped increase
absorption of the drug in the colon. The in vitro drug release
studies showed that only 10–12.5% of the metronidazole was
released on conditions representing the stomach and less than
25% was released in a simulated small intestine. However,
over 90% of the drug was rapidly released in cecal content.
Additional in vivo studies showed that the drug was only
released when the BAM reached the colon and was equally
pharmacologically effective compared to marketed
formulations.
Multiparticulate Systems
Multiparticulate systems have a smaller particle size com-
pared to single-unit systems, and studies have shown that they
can reach the colon more quickly since they pass through the
GI tract more easily (1,53). Microspheres are one example of
a multiparticulate system that can be loaded with a drug for
colonic delivery. Microspheres that are prepared using biode-
gradable components can be taken up by macrophages (1).
Chourasia et al. carried out in vitro drug-release studies on a
metronidazole multiparticulate system consisting of cross-
linked chitosan microspheres coated with pH-sensitive
Eudragit® polymers (52). Metronidazole was released only
after Eudragit® polymers dissolved in the alkaline pH of the
small intestine. Since there was increased drug release in the
presence of rat cecal contents, chitosan was thought to be
susceptible to degradation by colonic enzymes. Vaidya et al.
developed a multiparticulate system in which microspheres of
the polysaccharide pectin were coated with a pH-sensitive
polymer, Eudragit® S 100 (41,54). The in vitro drug release
studies showed that no metronidazole was released at the
acidic pH of the stomach. However, once the system was in
a more alkaline environment of the colon, metronidazole was
released continuously. Metronidazole release was found to be
even more significant in the presence of rat cecal contents
indicating that this system was biodegradable, in addition to
being pH-sensitive. Furthermore, the metronidazole concen-
tration in various parts of the GIT as shown through in vivo
studies also demonstrated the ability of this system to target
this drug specifically to the colon. Perera et al. synthesized and
evaluated microparticles based on a pectin-4-aminothiophenol
(Pec-ATP) conjugate and observed that these particles were
much more stable in vivo, than unmodified pectin micropar-
ticles (55). These particles thus appeared to be a better option
for colon-targeted delivery based on this study. In a recent
study, Liu et al. developed guar gum base microspheres for the
colonic delivery of budesonide (56). The in vitro release stud-
ies showed that these microspheres extended the release of
budesonide over 24 h. The in vivo evaluation of the colon
targeting and pharmacokinetic studies showed that the pre-
pared budesonide microspheres effectively delivered budeso-
nide to the colon in high concentrations.
Beckert et al. synthesized and evaluated a multiparticu-
late system in which the drug in the core of the formulation
consisted of two forms of pellets (57). The first type of pellet,
pellet A, contained an inner polymer coating which allowed
the drug to be released continuously and an outer polymer
which broke down only at a pH greater than 5.5. The polymer
coating on pellet B limited the drug release to less than 20%
after 6 h at pH 6.8. However, more than 50% of the drug was
released within the same time period at pH 7.2. Therefore, the
combination of these two forms of pellets with their polymer
coatings was found to be promising for a targeted drug deliv-
ery to the colon. Agarwal et al. in a recent study prepared and
characterized calcium alginate-carboxymethyl cellulose (CA-
CMC) beads for colon-specific oral drug delivery (58). The
researchers explored the combined properties of CA-CMC,
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i.e., pH sensitivity, degradation by colonic microflora, and
preferential colonic mucoadhesivity in designing colon-
specific delivery of 5-flurouracil, an anticancer drug. The
in vitro drug release results showed that the CA-CMC beads
were able to significantly extend the release of the drug be-
yond 24 h. Additionally, the CA-CMC beads were demon-
strated to have a significantly high mucoadhesiveness at
colonic pHand degrade in the presence of colonic microflora.
The use of nanoparticles as carriers for orally adminis-
tered drugs targeted to the colon has also been reported
previously (59–61). Studies have shown that these nanoparti-
culate systems improve the bioavailability of these drugs due
to their increased surface area and thus increased contact with
biological surfaces. Nanoparticles are also taken up by macro-
phages at inflamed regions of the colon, which allows the
system to remain at the target site for a prolonged period of
time. However, the nanoparticulate systems must be protected
from being taken up by Payer’s patches or degraded by
enzymes before reaching the colon in order for this approach
to be successful. Calabrese et al. prepared nanotechnology-
based hybrid formulations of metronidazole and K10-
montmorillonite (MMT-K10) clay, and carried out kinetic
and equilibrium studies to determine the release of MNE from
this clay (60). The results showed that these newer nanopar-
ticle formulations allowed for longer action in the colon. It was
also found that an enteric coating is unnecessary due to low
drug release in the simulated gastric fluid.
Polysaccharide-Based Delivery Systems
Polysaccharide-based delivery systems have several
advantages and are therefore becoming a popular option for
colon-specific delivery of drugs. Some of the advantages with
polysaccharide use include availability, easy modifications,
stability, safety, and biodegradability (4). Mundargi et al. com-
pared several polysaccharides for their usefulness in colon-
targeted metronidazole delivery (62). The results showed that
the release rate of metronidazole does depend on the nature
and the concentration of the polysaccharide used in the for-
mulation. Gauri et al. used various amounts of xanthan gum
and guar gum to prepare matrix tablets of metronidazole (63).
The in vitro evaluation of tablets in 0.1 N HCl, pH 7.4 phos-
phate buffer, and pH 6.8 phosphate buffer with 4% w/v rat
cecal content showed that the amount of drug released from
the matrix tablets during the first 5 h, which represented time
spent in the stomach and small intestine, ranged from 12 to
33%. It was also observed that the increasing xanthan gum
content in the matrix tablets delayed the drug release and
caused them to be more susceptible to colonic enzymes.
The use of a combination of polysaccharides in CDDS
has been found to be more effective for achieving colon-
specific delivery compared to the use of a single polysaccha-
ride. Cellulose derivatives are frequently used in combination
to develop these delivery systems because cellulose is not
absorbed systemically when administered orally. There are
two groups of cellulose esters which can be used in drug
formulations. Non-enteric cellulose esters such as cellulose
acetate are insoluble in water and their solubility is indepen-
dent of pH. These can be used in insoluble, permeable coat-
ings. The enteric cellulose esters such as cellulose acetate
phthalate (CAP) and hydroxypropyl methylcellulose
phthalate (HPMCP) have solubilities which are pH-depen-
dent. They are insoluble in highly acidic conditions, but when
the pH reaches a certain range they dissolve. The pH at which
the polymer dissolves varies depending on the extent of ester-
ification. Some examples of carbohydrate mixtures which
have been studied include pectin-HPMC, chitosan-HPMC,
chitosan-pectin, guar gum-chitosan, and dextran-chitosan
(64–66).
As mentioned in the previous sections, polysaccharides
such as pectin, chitosan, chondroitin sulfate, galactomannan,
and amylose are ideal materials for achieving colon-specific
delivery because they can be degraded by the colonic enzymes
and are harmless to the organisms. The use of these polysac-
charides in thin film coatings is believed to have the potential
to allow for increased drug delivery to the target regions at a
faster rate, compared to other formulations which utilize these
materials within matrix systems or as compression coatings.
Pectin is a hydrophilic polysaccharide which can modify
drug release due to its gelling ability. An insoluble poly-
mer such as ethyl cellulose (EC) is often mixed with the
pectin in the coating layer to help reduce water perme-
ability and protect the drug core (67). Wakerly et al.
mixed an aqueous dispersion of EC (Surelease®) with
pectin to coat tablets of paracetamol (68). These film
coatings had various pectin/EC ratios, and after evaluating
the coated tablets in vitro, the results showed that the rate of
drug release increased as the amount of pectin in the film
increased. The drug diffused through the EC as well as through
pores which formed in the film coating after pectinolytic
enzymes degraded the pectin (68).
Colon Targeting by Coatings
Incorporating the drug in the pH-sensitive polymers al-
low for delayed release by protecting the active ingredient
from the acidic pH of the stomach and proximal small intes-
tine. These polymers then break down in the more basic pH of
the terminal ileum, thus providing a targeted drug delivery to
the colon (1,3). Although the solubility of these polymers
increases as pH rises, there are some disadvantages to this
approach. The pH fluctuations along the GIT can cause the
formulation to dissolve early in the small intestine and the lag
time can be too long at the ileo-cecal junction and ascending
colon (4). Some examples of commonly used pH-sensitive
polymers in the design of colon-targeted drug delivery systems
include methacrylic-acid based polymers, also known as
Eudragit® (2,36).
Enteric-soluble polymers are resistant to dissolution in
the acidic environment of the stomach, but can dissolve at
the higher pH values of the intestine. These polymers have
been studied extensively for their use as coatings in formula-
tions intended to deliver active pharmaceutical ingredients
specifically to the colon (Fig. 1). Polymers based on poly-
methacrylate such as Eudragit® L and Eudragit® S have
frequently been used for this purpose, and each one has its
own unique pH value at which it dissolves. These two poly-
mers have been mixed in different ratios to form a coating
with an optimized dissolution rate. Additionally, coatings with
these polymers are designed to be relatively thick to prolong
their dissolution, and provide a controlled or an extended
drug release (69). Obitte et al. investigated the capability of
736 Amidon et al.
the hydrophobic polymers Landolphia owariensis latex (LOL)
and Eudragit® L-100 to control the release of metronidazole
aimed at colon targeting (70). The in vitro dissolution studies
showed that drug release increased with increasing pH. The
Eudragit® L 100 and LOL also demonstrated an additive
effect on delaying and then increasing drug release at pH 7.4
over an extended period of time.
In addition to enteric-soluble polymers, acid-soluble pol-
ymers have also been investigated as potential agents to be
used in colon-targeted formulations. The pH of the proximal
large intestine decreases in those with IBS. For example, the
colonic pH is typically 6.4–7.0 for a healthy person, but can
drop to 2.3–4.7 with someone who has UC (71). Leopold et al.
developed dexamethasone minitablets coated with the acid-
soluble polymer Eudragit® E and found that the Eudragit® E
coating rapidly dissolved in the buffers at pH 2.0–5.0 allowing
the drug to be released within 10–50 min. However, the extent
to which the drug released was delayed in the pH 6.8 buffer
depended on the composition of the drug core as well as the
coating thickness. (69,71).
Compression-coating (tablet-in-a-tablet), also known as
Bdry coating^ is a tablet coating technique where the core
tablet (containing the drug) is coated with a coating-
excipient (powder) on a tablet press. This technique has
gained interest in the formulation development in recent years
due to the dry nature of dosage form development, i.e., avoid-
ing the process complexities and stability challenges associat-
ed with spray coatings (wet, hot). Several researchers have
explored this technique for the development of colon-specific
oral solid dosage formulations.
Yassin et al. applied a granulated chitosan coating to a
colon-targeted tablet formulation of 5-fluorouracil using
compression-coating with a goal of targeting this drug specif-
ically to the colon for a more effective treatment of colon
cancer with less toxic side effects (72). The in vitro evaluation
of the formulation showed that increasing the thickness of the
coating resulted in a progressive decrease in the drug release
at acidic pH. Additionally, the in vivo studies showed that this
formulation did not break down until it reached the large
bowel. Recently, Kadiyam et al. developed an almond-gum,
matrix-based colonic drug delivery system of tramadol HCl,
compression-coated with Eudragit® S100 (73). The study
results showed that compression-coated tablets successfully
delayed the release of tramadol HCl over 24 h. The in vivo
X-ray imaging studies in rats revealed that the compression-
coated tablets efficiently delivered the drug to the colon with-
out being disintegrated in the upper GIT.
Pulsatile drug delivery systems are time-dependent for-
mulations that are designed to release the drug after a pre-
dictable period known as the Blag phase^ (74). The pulsatile
systems which are currently being studied do not depend on
the different environmental conditions of the GIT for the drug
release. Most of these orally administered systems consist of a
drug-containing core, coated with a polymer (74). Film coat-
ings used for pulsatile delivery include rupturable, permeable,
and semipermeable coatings.
Rupturable film coatings allow a drug to be released after
undergoing a timed disruption caused by hydrostatic pressure
within the core (69). Since these polymeric films are perme-
able, an influx of water and subsequent swelling of the hydro-
philic polymers can initiate the disruption. Permeable film
coatings allow water to pass through and dissolve the drug-
containing core, but the polymeric coating itself is insoluble.
These coatings do not rupture after exposure to an aqueous
medium because they are permeable and resistant to dissolu-
tion. Additionally, the materials within these coatings do not
expand after an influx of water. Since it takes time for the drug
to diffuse out from the core after dissolving, this results in a lag
phase before drug release occurs (69).
Another type of time-dependent coating is a semiperme-
able film coating which is similar to permeable coatings in that
they are permeable to water (75). However, these coatings are
impermeable to solutes. Water moves into the tablet core of
the formulation due to osmotic pressure, and when the hydro-
static pressure within the system exceeds the osmotic pressure
after a programmed lag phase, small orifices in the outer
membrane allow the drug which has dissolved in the aqueous
medium to be pumped out (76).
INTEGRATED APPROACHES FOR ACHIEVING
COLONIC DELIVERY
In recent years, several integrated approaches have been
explored to achieve colon-specific drug delivery. These
approaches utilize physiological factors such as luminal pres-
sure, or physical phenomena such as osmotic pressure in the
design of the delivery systems.
Pressure Controlled Delivery
Peristaltic motion causes the luminal pressure of the large
intestine to increase more than that of the small intestine
because its contents are more viscous due to the reabsorption
of water (77). Several studies have been carried out to utilize
the colonic luminal pressure to develop colon-specific drug
delivery systems. Takaya et al. developed capsules that deliver
a drug to the colon based on luminal pressure (78). Although
these systems allow for drugs to be delivered to the colon
rather than the small intestine due to higher colonic pressure,
reabsorption of water from the colon causes its content to be
highly viscous which may become an obstacle for site-specific
delivery (4,79).
Fig. 1. Schematic representation of the cross-section of the enteric-coated colon-targeted drug
delivery system
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Osmotic Controlled Delivery
Although the concept of osmotic controlled drug delivery
has been around for several years, the applications of this tech-
nology in the design of colon-specific oral dosage forms have
gained popularity only in the 10–15 years. The OROS-CT is an
example of a system regulated by osmotic pressure. It consists of
a hard gelatin capsule which dissolves in the pH of the small
intestine and allows water to enter the unit. This then causes it to
swell and the drug is forced out (3). Within each capsule there
can be as many as 5–6 units, and each unit is surrounded by a
drug impermeable enteric coating which prevents water from
entering in the acidic environment of the stomach (Fig. 2).
However, this coating dissolves and the water enters once the
capsule enters the higher pH of the small intestine. Within the
enteric coating there is a semipermeable membrane which
encompasses an osmotic push compartment as well as a drug
compartment. The water causes the push compartment to swell
and forms a gel in the drug compartment that is forced out of an
orifice through the membrane next to the drug compartment.
The rate at which the drug flows out depends on the rate at
which water enters. To prevent drug release in the small intes-
tine, these systems can also be designed such that there is a lag
time between when the enteric coating dissolves and the drug is
released (80).
Pulsincap Systems
Time-dependent systems are not always ideal for delivering
drugs to the colon due to variability in the gastric emptying time
and the changes in gastrointestinal transit due to peristalsis or
disorders such as IBS. Therefore, the integration of a timed-
Fig. 2. Schematic representation of the cross-section of the OROS-CTcolon-targeted drug delivery system
Fig. 3. Schematic representation of the mechanism of the pulsincap colon-targeted drug delivery system
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release system with pH-sensitive properties can be beneficial in
achieving colon-targeted delivery. A pulsincap system is one
example of a formulation that utilizes both these techniques
(81,82). The system consists of a water insoluble capsule body
containing the drug, a hydrogel plug which seals the opened end
of this capsule body and a water soluble cap which covers the
hydrogel plug (Fig. 3). Additionally, the capsule is coated with an
acid insoluble film coating which prevents the drug from being
released in the stomach. The hydrogel plug begins swelling when
this enteric coating dissolves in the small intestine. The swelling
of the plug allows for a lag time before the drug is released and
the amount of lag time depends on the length of the plug and the
extent at which it is inserted (81). Abraham et al. developed a
pulsincap system in which they tested several polymers as the
plug material. The formulations were tested at pH 1.2 for 2 h to
simulate gastric fluid, pH 7.4 for 3 h to simulate intestinal fluid,
and pH 6.8 for 7 h to simulate the colon. The study found that no
significant drug release occurred within 5 h from the start of the
experiment, and it was concluded that this modified pulsincap
system can successfully target metronidazole to the colon (81).
CONCLUSIONS
The development of colon-targeted oral drug delivery
systems has gained increasing interest among formulation
scientists in recent years. As discussed above, colon-specific
drug delivery systems provide significant therapeutic benefits
to the patients in terms of safety, efficacy, and patient compli-
ance. Factors including the physicochemical characteristics of
the drug, formulation and process variables, as well as the GI
physiological factors influence, and may present a challenge to
the successful formulation of a colon-specific drug delivery
system. The formulation approaches utilized to overcome
these challenges mainly focus on an individual mechanism of
drug delivery, including bypassing the complex pH environ-
ment of the upper GIT by the dosage form, preventing the
drug release and drug-absorption in the upper GIT, and re-
leasing the drug in the colon for absorption. The metabolizing
capacity of the colon enzymes is also being explored as an
approach to target drug delivery specifically in the colonic
region. To ensure a balance between efficiency, target-speci-
ficity, cost, and patient compliance, it appears that a combina-
tion of conventional and newer approaches is the key to the
development of colon-specific drug delivery systems. In addi-
tion to the combined approaches, the exploration of nanotech-
nology seems to be an area of future research for colon
targeting of drugs (59–61,83).
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